Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open-label, single-arm phase II study of bipolar androgen therapy (BAT) given in addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma Enzyme-linked Immunospot (ELISPOT) response rate to PA2024 (an engineered fusion protein of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor which the activated autologous dendritic cells in the Sipuleucel-T vaccine are loaded with) in patients with metastatic castration resistant prostate cancer (mCRPC).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent wyraża zgodę na udział w badaniu.
- •Rak prostaty potwierdzony w badaniu histologicznym.
- •Zaawansowana choroba nowotworowa z przerzutami do kości lub innych tkanek.
- •Zaawansowany rak prostaty, który przestał reagować na leczenie obniżające poziom testosteronu.
- •Poziom testosteronu poniżej 50 ng/dL (potwierdzenie stanu kastracji).
- •Ogólny stan zdrowia pacjenta dobry (według skali ECOG 0 lub 1).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Yale Cancer Center
New Haven, United States
Trial contact
Laura Kane
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.